Stockreport

RLYB Ends Pregnancy-Related Rare Disease Program, Stock Tanks [Yahoo! Finance]

Rallybio Corporation  (RLYB) 
PDF The company decided to stop the development of RLYB212 after pharmacokinetic (PK) data from a phase II study showed that treatment with the candidate failed to achieve [Read more]